FUNDAMENTALS · Fundamentals · US Healthcare

Henry Schein (HSIC) Fundamentals 2026 — P/E 25.4x, Revenue Analysis | SniperIQ

Henry Schein (HSIC) is a US-listed Healthcare company in Medical - Distribution with a market capitalization of $9.6B, trading at $84.69 on the NASDAQ. This SniperIQ fundamentals page covers Henry Schein's valuation (P/E 25.4x, P/B 3.0x), profitability (net margin 3.0%), revenue (

3.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$9.6B
P/E (TTM)25.4x
Net Margin3.0%
Revenue (FY25)
3.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Henry Schein's market cap?

Henry Schein (HSIC) has a market capitalization of approximately $9.6B, trading at $84.69 on the NASDAQ. Market cap moves with the live share price.

What is Henry Schein's P/E ratio?

Henry Schein's trailing twelve-month P/E ratio is 25.4x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Henry Schein?

Henry Schein runs a net profit margin of 3.0%, a gross margin of 29.7%, and an operating margin of 5.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Henry Schein generate?

Henry Schein reported revenue of

3.2B for fiscal year 2025, with net income of
98M and earnings per share (EPS) of 3.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Henry Schein pay a dividend?

Henry Schein does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Henry Schein financially healthy?

Henry Schein carries a debt-to-equity ratio of 1.15x and a current ratio of 1.36x, with a market beta of 0.81. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Henry Schein a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Henry Schein (HSIC) the key facts are: market cap $9.6B, P/E 25.4x, revenue

3.2B, 52-week range 61.95-89.34. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Henry Schein's full fundamentals live

Get Henry Schein's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.